From Bench to Bedside: Immunotherapy for Prostate Cancer

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tse, Brian Wan-Chi, Jovanovic, Lidija, Nelson, Colleen Coyne, de Souza, Paul, Power, Carl Andrew, Russell, Pamela Joan
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2014
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4168152/
https://ncbi.nlm.nih.gov/pubmed/25276838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/981434
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados